查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083876

疼痛管理治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、適應症、通路和最終用戶分類）

Pain Management Therapeutics Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，疼痛管理治療市場將成長至 1,267.5 億美元，複合年成長率為 5.00%。

主要市場統計數據
基準年 2025 900.7億美元
預計年份：2026年 937.8億美元
預測年份：2032年 1267.5億美元
複合年成長率 (%) 5.00%

疼痛管理治療執行摘要

慢性疼痛的全球負擔、人口老化、肌肉骨骼疾病的增加、神經病變相關疼痛、術後疼痛、神經性疼痛和偏頭痛等因素正在改變疼痛管理和治療市場。檢驗的公共衛生證據凸顯了市場的規模。根據美國疾病管制與預防中心 (CDC) 統計，2021 年美國有 20.9% 的成年人患有慢性疼痛。世界衛生組織 (WHO) 和國際疼痛研究協會 (IASP) 也認定疼痛是導致殘疾、生活品質下降和功能障礙的主要原因之一。

疼痛管理領域的變革性變化

疼痛管理治療領域正經歷著從症狀抑製到精準、實證和個人化治療的結構性轉變。監管機構、保險公司和臨床醫生都在優先考慮非鴉片類鎮痛藥、防濫用製劑、更安全的製劑方案以及針對神經病變疼痛、發炎性疼痛、傷害性疼痛和混合性疼痛機制的療法。

人工智慧（AI）的累積影響

人工智慧 (AI) 正在對疼痛管理的各個領域產生累積影響，包括藥物發現、臨床開發、製劑支援和病患監測。透過利用 AI 進行標靶識別、分子篩檢、臨床試驗可行性分析以及從真實世界數據中提取洞見，可以降低識別疼痛表現型和治療反應模式的不確定性。

區域疼痛管理和治療的關鍵見解。

由於亞太地區人口眾多，日本、中國、韓國和澳洲等國人口老化速度加快，以及印度和東南亞地區專科醫療服務覆蓋範圍不斷擴大，該地區正成為疼痛管理治療的重點市場。骨關節炎、下背痛、糖尿病神經病變、偏頭痛、癌症疼痛和術後疼痛是推動市場需求的主要因素，而價格優勢、多樣化的報銷機制和局部化的製劑管道也持續推動著產品的市場滲透。

關鍵經濟和戰略集團洞察

在東協，隨著醫療保險覆蓋範圍的擴大和慢性病盛行率的上升，對價格合理的止痛藥、神經病變治療、偏頭痛治療以及術後疼痛管理的需求日益成長。由於各成員國在保險報銷制度、藥房資源和藥品配製基礎設施方面存在顯著差異，該地區的商業策略需要採取差異化定價、與當地機構建立合作關係以及開展以教育為基礎的推廣活動。

主要市場的關鍵國別洞察

美國是疼痛管理治療的核心市場，這得益於其慢性疼痛的高發生率、完善的專科醫療體系、活躍的臨床研究以及對鴉片類藥物合理使用的嚴格監管。加拿大同樣重視安全性，同時注重公共醫療保險報銷和實證製劑。墨西哥和巴西為品牌學名藥、抗發炎藥、神經病變疼痛治療​​、偏頭痛治療以及醫院疼痛管理提供了不斷成長的市場機會。

為行業領導者提供的實用建議

產業領導者應優先開發差異化的非鴉片類藥物和鴉片類藥物減量產品系列，並以可靠的臨床終點、真實世界數據和安全性數據為支持。研發項目應根據疼痛機制、共病、功能障礙和治療史對患者進行細分，以提高臨床試驗的成功率及其對支付者的相關性。

調查方法

本執行摘要基於系統的二次調查和資訊來源(CDC)、美國國立衛生研究院 (NIH)、美國食品藥品監督管理局 (FDA)、歐洲藥品管理局 (EMA) 和經濟合作暨發展組織 (OECD) 等權威機構的健康數據、各國衛生機構、同行評審機構的臨床監管機構資訊以及同行評審機構的健康資料、臨床監管機構、同行評審機構的臨床管理機構、同行評審機構的健康檢驗研究結果從治療細分、疾病負擔、相容性趨勢、報銷、安全監測和區域可近性等方面進行了評估。

結論

疼痛管理正進入一個新階段，其特徵是安全性、個體化、非鴉片類藥物的創新以及實證用藥。由於慢性疼痛和急性疼痛持續給已開發國家和新興國家的醫療保健系統帶來巨大的臨床、經濟和社會負擔，因此該市場仍然至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 疼痛管理與治療市場：依藥物類別分類

  • 輔助止痛藥
  • 局部麻醉劑
  • 神經病變疼痛的治療
    • 抗驚厥藥物
    • 抗憂鬱症
  • 非類固醇類抗發炎藥
    • COX-2抑制劑
    • 傳統非類固醇抗發炎藥
  • 鴉片類藥物
    • 強效鴉片類藥物
    • 弱鴉片類藥物

第8章 疼痛管理治療市場：依給藥途徑分類

  • 口服
  • 腸外
    • 肌肉內部
    • 靜脈
    • 皮下
  • 外用
  • 經皮給藥

第9章 疼痛管理治療市場：依適應症分類

  • 急性疼痛
  • 慢性疼痛
    • 腰痛
    • 神經性慢性疼痛
    • 骨關節炎
    • 類風濕性關節炎
  • 發炎性疼痛
  • 神經病變疼痛

第10章 疼痛管理治療市場：依通路分類

  • 離線
  • 線上

第11章 疼痛管理與治療市場：依最終使用者分類

  • 門診手術中心
  • 居家醫療
    • 安寧療護
    • 病人家
  • 醫院
    • 私立醫院
    • 公立醫院

第12章 疼痛管理治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 疼痛管理與治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 疼痛管理與治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Assertio Holdings, Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boston Scientific Corporation
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Endo International plc
  • Fresenius Kabi AG
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • Lupin Limited
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
Product Code: MRR-431388EE3C5C

The Pain Management Therapeutics Market is projected to grow by USD 126.75 billion at a CAGR of 5.00% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 90.07 billion
Estimated Year [2026] USD 93.78 billion
Forecast Year [2032] USD 126.75 billion
CAGR (%) 5.00%

Pain Management Therapeutics Executive Summary

Pain management therapeutics are being reshaped by the global burden of chronic pain, aging populations, rising musculoskeletal disorders, cancer-related pain, postsurgical pain, neuropathic pain, and migraine. Verified public-health evidence underscores the scale: the U.S. CDC reported that 20.9% of U.S. adults experienced chronic pain in 2021, while the WHO and IASP recognize pain as a major driver of disability, reduced quality of life, and reduced functional capacity.

The market is moving beyond conventional opioid-centered care toward multimodal pain management, including nonsteroidal anti-inflammatory drugs, acetaminophen, anticonvulsants, antidepressants, topical analgesics, local anesthetics, biologics, neuromodulation-adjacent therapeutics, and digital pain support tools. Commercial success increasingly depends on demonstrating measurable outcomes, safety, real-world effectiveness, and alignment with opioid stewardship policies.

Transformative Shifts in the Pain Therapeutics Landscape

The pain management therapeutics landscape is undergoing a structural shift from symptom suppression to precision, evidence-led, and patient-specific treatment pathways. Regulators, payers, and clinicians are prioritizing non-opioid analgesics, abuse-deterrent formulations, safer prescribing protocols, and therapies that address neuropathic, inflammatory, nociplastic, and mixed pain mechanisms.

Scientific progress is also changing competitive positioning. CGRP-targeted migraine therapies, sodium-channel research, cannabinoid-based programs where permitted, extended-release local anesthetics, and repurposed neuromodulatory medicines are expanding the innovation pipeline. At the same time, formulary access is increasingly tied to comparative effectiveness, pharmacovigilance, and health-economic evidence rather than brand recognition alone.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across pain therapeutic discovery, clinical development, prescribing support, and patient monitoring. AI-enabled target identification, molecular screening, trial feasibility analytics, and real-world evidence mining can reduce uncertainty in identifying pain phenotypes and treatment-response patterns.

In clinical and commercial use, AI supports risk stratification for opioid misuse, adverse-event detection, dose optimization, and remote symptom tracking through digital health platforms. The impact is not a single disruption but an accumulating advantage: organizations that combine compliant data governance, validated algorithms, and clinician oversight can improve trial design, personalize therapy selection, and strengthen payer evidence packages.

Key Regional Insights for Pain Management Therapeutics

Asia-Pacific is becoming a high-priority arena for pain management therapeutics due to population scale, rapid aging in Japan, China, South Korea, and Australia, and expanding access to specialty care in India and Southeast Asia. Demand is supported by osteoarthritis, low back pain, diabetic neuropathy, migraine, cancer pain, and postsurgical pain, while affordability, reimbursement diversity, and local prescribing pathways continue to shape product uptake.

North America remains the most evidence-intensive and policy-sensitive region, led by the United States and Canada. The region combines high chronic pain prevalence, advanced specialty prescribing, strong adoption of migraine and biologic therapies, and rigorous opioid-risk controls. Latin America, led by Brazil and Mexico, is expanding access through public and private channels, though budget constraints, fragmented reimbursement, and uneven specialist availability influence adoption.

Europe is shaped by aging demographics, strong health technology assessment requirements, and country-specific reimbursement pathways across Germany, France, Italy, Spain, and the United Kingdom. The Middle East, particularly GCC health systems, is investing in hospital capacity, oncology care, and specialty clinics, supporting higher-value pain therapies with clear clinical evidence. Africa remains access-constrained but shows sustained need for affordable analgesics, palliative care medicines, essential pain education, and stronger supply continuity.

Key Economic and Strategic Group Insights

ASEAN markets show rising demand for affordable pain medicines, diabetic neuropathy treatment, migraine care, and postoperative pain control as healthcare coverage expands and chronic disease prevalence grows. Commercial strategies in the region require differentiated pricing, local partnerships, and education-led adoption because reimbursement, pharmacy access, and prescribing infrastructure differ widely among member states.

The GCC is increasingly aligned with specialty-care modernization, oncology investment, and hospital-based pain services, making it attractive for premium therapeutics with strong clinical evidence and safety profiles. The European Union is defined by regulatory harmonization through centralized and national procedures but commercial fragmentation through national HTA and reimbursement systems, requiring country-level evidence planning and early payer engagement.

BRICS countries represent large-volume access opportunities, with China, India, and Brazil offering population scale and Russia and South Africa contributing distinct affordability, procurement, and access dynamics. G7 markets remain the benchmark for innovation uptake, pharmacovigilance, controlled-substance oversight, and payer scrutiny. NATO countries overlap heavily with advanced European and North American systems, where supply security, controlled-medicine governance, and resilient pharmaceutical logistics are strategic priorities for pain management therapeutics.

Key Country Insights Across Priority Markets

The United States is the central market for pain management therapeutics due to high chronic pain prevalence, advanced specialist care, extensive clinical research activity, and strong regulatory attention to opioid stewardship. Canada follows similar safety priorities while emphasizing public reimbursement and evidence-based prescribing. Mexico and Brazil offer expanding access opportunities across branded generics, anti-inflammatory drugs, neuropathic pain medicines, migraine therapies, and hospital-based pain management.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are influenced by national health systems, HTA standards, and aging populations with a high musculoskeletal pain burden. Germany remains important for early European launch strategy, while France, Italy, and Spain require strong reimbursement dossiers and comparative clinical evidence. Russia presents demand for affordable and locally accessible pain therapies amid a complex regulatory, procurement, and operating environment.

China and India are major long-term priority markets because of population scale, diabetes-related neuropathy, cancer care expansion, musculoskeletal disease burden, and rising urban healthcare access. Japan has high demand associated with aging, osteoarthritis, neuropathic pain, postsurgical pain, and migraine management. Australia and South Korea offer sophisticated regulatory systems, high digital-health readiness, and opportunities for evidence-backed specialty therapies supported by real-world outcomes and clinician education.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated non-opioid and opioid-sparing portfolios supported by robust clinical endpoints, real-world evidence, and safety data. Development programs should segment patients by pain mechanism, comorbidities, functional impairment, and treatment history to improve trial success and payer relevance.

Organizations should invest in AI-enabled evidence generation, pharmacovigilance, and patient-reported outcome platforms while maintaining transparent governance and regulatory validation. Market access teams need region-specific reimbursement strategies, education programs for clinicians, and partnerships with health systems to support responsible prescribing, adherence, and measurable functional outcomes.

Research Methodology

The executive summary is based on structured secondary research and evidence triangulation using authoritative sources such as WHO, CDC, NIH, FDA, EMA, OECD health data, national health agencies, peer-reviewed journals, clinical trial registries, and public regulatory guidance. Insights were evaluated for relevance to therapeutic classes, disease burden, prescribing behavior, reimbursement, safety monitoring, and regional access conditions.

The methodology emphasizes verified public-health indicators, regulatory trends, clinical evidence, and commercially observable market dynamics. Qualitative interpretation was applied to identify strategic implications while avoiding unsupported market-size claims, market share estimates, or unverified projections.

Conclusion

Pain management therapeutics are entering a new phase defined by safety, personalization, non-opioid innovation, and evidence-based access. The market remains essential because chronic and acute pain continue to impose substantial clinical, economic, and social burden across developed and emerging healthcare systems.

Organizations that combine scientifically differentiated therapies, responsible opioid stewardship, AI-supported evidence generation, and region-specific commercialization will be best positioned to achieve sustainable competitiveness. The next advantage will come from proving not only analgesic efficacy but also functional improvement, safety, adherence, patient experience, and value for payers and patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pain Management Therapeutics Market, by Drug Class

  • 7.1. Adjuvant Analgesics
  • 7.2. Local Anesthetics
  • 7.3. Neuropathic Pain Agents
    • 7.3.1. Anticonvulsants
    • 7.3.2. Antidepressants
  • 7.4. Nonsteroidal Anti-Inflammatory Drugs
    • 7.4.1. Cox-2 Inhibitors
    • 7.4.2. Traditional NSAIDs
  • 7.5. Opioids
    • 7.5.1. Strong Opioids
    • 7.5.2. Weak Opioids

8. Pain Management Therapeutics Market, by Route Of Administration

  • 8.1. Oral
  • 8.2. Parenteral
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
    • 8.2.3. Subcutaneous
  • 8.3. Topical
  • 8.4. Transdermal

9. Pain Management Therapeutics Market, by Indication

  • 9.1. Acute Pain
  • 9.2. Chronic Pain
    • 9.2.1. Low Back Pain
    • 9.2.2. Neuropathic Chronic Pain
    • 9.2.3. Osteoarthritis
    • 9.2.4. Rheumatoid Arthritis
  • 9.3. Inflammatory Pain
  • 9.4. Neuropathic Pain

10. Pain Management Therapeutics Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Pain Management Therapeutics Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Care Settings
    • 11.2.1. Hospice Care
    • 11.2.2. Patient Home
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Pain Management Therapeutics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Pain Management Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pain Management Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. AbbVie Inc.
  • 16.3. Amgen Inc.
  • 16.4. Assertio Holdings, Inc.
  • 16.5. AstraZeneca plc
  • 16.6. Aurobindo Pharma Limited
  • 16.7. Bayer AG
  • 16.8. Boston Scientific Corporation
  • 16.9. Cipla Limited
  • 16.10. Daiichi Sankyo Company, Limited
  • 16.11. Dr. Reddy's Laboratories Limited
  • 16.12. Eli Lilly and Company
  • 16.13. Endo International plc
  • 16.14. Fresenius Kabi AG
  • 16.15. GlaxoSmithKline plc
  • 16.16. Grunenthal GmbH
  • 16.17. Hikma Pharmaceuticals PLC
  • 16.18. Johnson & Johnson Services, Inc.
  • 16.19. Kyowa Kirin Co., Ltd.
  • 16.20. Lupin Limited
  • 16.21. Mallinckrodt plc
  • 16.22. Merck & Co., Inc.
  • 16.23. Novartis AG
  • 16.24. Pfizer Inc.
  • 16.25. Purdue Pharma L.P.
  • 16.26. Sanofi S.A.
  • 16.27. Sun Pharmaceutical Industries Ltd.
  • 16.28. Takeda Pharmaceutical Company Limited
  • 16.29. Teva Pharmaceutical Industries Ltd.
  • 16.30. Vertex Pharmaceuticals Incorporated
  • 16.31. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADJUVANT ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADJUVANT ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADJUVANT ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROPATHIC PAIN AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROPATHIC PAIN AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROPATHIC PAIN AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COX-2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COX-2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COX-2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRADITIONAL NSAIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRADITIONAL NSAIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRADITIONAL NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL STRONG OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL STRONG OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STRONG OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL WEAK OPIOIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL WEAK OPIOIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL WEAK OPIOIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHRONIC PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHRONIC PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LOW BACK PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LOW BACK PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LOW BACK PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROPATHIC CHRONIC PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROPATHIC CHRONIC PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROPATHIC CHRONIC PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLAMMATORY PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFLAMMATORY PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLAMMATORY PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROPATHIC PAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPICE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPICE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPICE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PATIENT HOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PATIENT HOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PATIENT HOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 212. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 214. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 217. GCC PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 251. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 253. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 262. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 264. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 265. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 266. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 296. CANADA PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 322. BRAZIL PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NEUROPATHIC PAIN AGENTS, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED KINGDOM PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 338.